UroAlert - GU Oncology Weekly

November 05, 2025

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Outcomes Among Rural and Urban Patients with High-risk NMIBC: Results from the Canadian Bladder Cancer Information System (CBCIS).

An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer.

Intratumoral expression of a composite B cell / CD8 T cell biomarker stratifies overall survival by ctDNA status and benefit from adjuvant immunotherapy in high risk, muscle invasive urothelial carcinoma.

The Interplay of Cumulative Perioperative Morbidity and Health-related Quality of Life After Radical Cystectomy-Prospective Evidence from the COMPACT Registry.

Development and external validation of a FISH-clinical nomogram for predicting overall survival in bladder cancer patients after radical cystectomy.

French recommendations of the AFU Oncology Committee FOR bladder Cancer: update 2025.

The clinical relevance of tertiary lymphoid structures in assessing treatment response in muscle invasive bladder cancer.

Evaluating the Long-Term Utility and Cost-Effectiveness of Computed Tomography (CT) Surveillance Beyond Five Years After Radical Cystectomy: A 10-Year Follow-Up Study.

Penile & Urethral Cancers

Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma.

Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma.

Renal Cancer

HIF2α inhibits glutaminase clustering in mitochondria to sustain growth of clear cell Renal Cell Carcinoma.

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).

Impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: a SIOP-RTSG radiotherapy committee study.

A cost-effectiveness comparison between immunotherapy combination regimens and sunitinib for advanced renal cell carcinoma in the USA and China.

Orthopedic interventions and outcomes in patients with metastatic renal cell carcinoma: a systematic review.

The Current Role of Renal Mass Biopsy.

Imaging Biomarkers in Evaluation of Malignancy and Aggressiveness in Renal Masses.

Prostate Cancer

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.

Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.

American Brachytherapy Society Education Committee Technical Report: A Resident's Guide to Evaluation of Prostate Low-Dose-Rate Brachytherapy Treatment Plans.

Emerging Robotic Platforms in Radical Prostatectomy: A Comparative Systematic Review and Network Meta-Analysis.

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment

Early Clinical Trial Tests Immune-Boosting Therapy Before Prostate Cancer Surgery

SpectronRx Begins Commercial-Scale Production of High-Purity Actinium-225, Strengthening Global Supply for Cancer Therapies

Experimental investigation of real-time 3D beam's eye view image-guided radiotherapy for prostate SBRT.

RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.

Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.

Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial.

Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.

Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.

Enhancing nerve sparing in robotic prostate surgery: the impact of NeuroSAFE on fascia preservation score.

Prognostic Impact of Biopsy Gleason 4 + 5, 5 + 4, and 5 + 5 in Grade Group 5 after Radical Prostatectomy.

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

Utility of the PROSTest, a Novel Blood-Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease.

HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.

Stereotactic ablative body radiotherapy for PSMA-PET/CT staged, oligometastatic prostate cancer - A multi-centre study.

Integration of Habitat Risk Score (HRS) in Radiotherapy for Prostate Cancer.

Biparametric MRI in prostate cancer: utility of whole-prostate and whole-lesion histogram and texture analysis for clinically significant prostate cancer.

Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy.

Upper Tract Tumors

Adjuvant treatment preferences in high-risk Upper Tract Urothelial Carcinoma: the perspective of Portuguese Medical Oncologists.

Testicular Cancer

Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma.

Adverse Events in Testicular Cancer Survivors Using EORTC QLQ-TC26: A Multi-Institutional, Cross-Sectional Study in Japan.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC